Sorivudine
Sorivudine (INN), is a nucleoside analogue antiviral drug, marketed under trade names such as Usevir (Nippon Shoji, Eisai) and Brovavir (BMS). It is used for the treatment of varicella zoster virus infections.[1]
Clinical data | |
---|---|
Trade names | Usevir, Brovavir |
Other names | BV-araU, Bromovinyl araU, 5-Bromovinyl-araU, 5-[(E)-2-bromoethenyl]-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione |
Routes of administration | Oral |
ATC code |
|
Pharmacokinetic data | |
Metabolism | Viral thymidine kinase |
Excretion | Kidney |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C11H13BrN2O6 |
Molar mass | 349.137 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(what is this?) (verify) |
Pharmacology
Feature
- First-line treatment of herpes drug acyclovir was (Zovirax, Activir) from VZV strong activity of the virus.
- Undergoes gastrointestinal absorption, absorption from the gastrointestinal tract after the most degrading without being excreted in urine.
Mechanism of action
- Sorivudine is phosphorylated by thymidine kinase activity in the body and is absorbed into the virus's DNA instead of the correct nucleoside. It is a competitive inhibitor of DNA polymerase, so the viral DNA cannot be replicated and the virus cannot grow.
Microbiology
Sorivudine is active against most species in the herpesvirus family.
- Herpes simplex virus type I (HSV-1)
- Varicella zoster virus (VZV)
- Epstein–Barr virus (EBV)
Interactions
Sorivudine interacts strongly and in some cases lethally with fluorouracil (5-FU), its prodrugs and related substances. This is based on the metabolite bromovinyluracil (BVU), which irreversibly inhibits the enzyme dihydropyrimidine dehydrogenase (DPD) which is necessary for inactivating 5-FU. The closely related drug brivudine has the same interaction.[2]
References
- Whitley RJ (1996). "Sorivudine: a potent inhibitor of varicella zoster virus replication". Advances in Experimental Medicine and Biology. 394: 41–4. doi:10.1007/978-1-4757-9209-6_5. PMID 8815706.
- "UAW – Aus Fehlern lernen - Potenziell tödlich verlaufende Wechselwirkung zwischen Brivudin (Zostex) und 5-Fluoropyrimidinen" (PDF). Deutsches Ärzteblatt (in German). 103 (27). 7 July 2006.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.